{"id":"azd0120","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Retinal toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FGFR1 is frequently dysregulated in certain cancers through gene amplification or translocation, driving proliferation and survival. AZD0120 selectively targets FGFR1 to inhibit downstream signaling pathways, inducing cell cycle arrest and apoptosis in FGFR1-dependent tumors. This approach is designed to provide clinical benefit in cancers with FGFR1 alterations while minimizing off-target effects.","oneSentence":"AZD0120 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cancer cells dependent on FGFR1 activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:39.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR1-amplified or FGFR1-altered solid tumors"}]},"trialDetails":[{"nctId":"NCT07250269","phase":"PHASE1","title":"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2025-10-29","conditions":"Relapsed/Refractory AL Amyloidosis","enrollment":9},{"nctId":"NCT07081646","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-18","conditions":"Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis","enrollment":91},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT07073547","phase":"PHASE1","title":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-31","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT06897930","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-21","conditions":"Lupus Erythematosus, Systemic","enrollment":150},{"nctId":"NCT07295847","phase":"PHASE1","title":"A Study of AZD0120 in Autoimmune Diseases","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-09","conditions":"Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT07224373","phase":"PHASE1","title":"An Open-label Study of AZD0120 in Adults With Multiple Sclerosis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-09","conditions":"Multiple Sclerosis","enrollment":24},{"nctId":"NCT07350837","phase":"EARLY_PHASE1","title":"CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-31","conditions":"Highly Sensitized Patients Awaiting Kidney Transplant","enrollment":12},{"nctId":"NCT05850234","phase":"PHASE1, PHASE2","title":"A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-20","conditions":"Relapsed/ Refractory Multiple Myeloma","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GC012F"],"phase":"phase_3","status":"active","brandName":"AZD0120","genericName":"AZD0120","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"AZD0120 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cancer cells dependent on FGFR1 activation. Used for FGFR1-amplified or FGFR1-altered solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}